General Information of DTT (ID: TT2THBD)

DTT Name P2X purinoceptor 3 (P2RX3) DTT Info
Gene Name P2RX3

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
6 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefapixant DM4GWL7 Cough MD12 Phase 3 [1]
BAY-1902607 DMYSQMW Cough MD12 Phase 2 [1]
BAY 1902607 DMFA4CK Cough MD12 Phase 1/2 [1]
AF-130 DM8LG2I Hypertension BA00-BA04 Phase 1 [2]
BAY 1817080 DMF9ALP Cough MD12 Phase 1 [3]
BAY-1817080 DMNL5G7 Endometriosis GA10 Phase 1 [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
13 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AF353 DMXQ3MO Discovery agent N.A. Investigative [4]
AVVYPWT DMK9BMQ Discovery agent N.A. Investigative [5]
BzATP DM37GYA Discovery agent N.A. Investigative [6]
Cyclic LVVYPWT DM2JE5F Discovery agent N.A. Investigative [5]
ISOPPADS DMWI0M8 Discovery agent N.A. Investigative [7]
LAVYPWT DMOK6IP Discovery agent N.A. Investigative [5]
LVAYPWT DMIO405 Discovery agent N.A. Investigative [5]
LVVAPWT DM78Z9D Discovery agent N.A. Investigative [5]
LVVYPWT DM1QPG7 Discovery agent N.A. Investigative [5]
MK-3901 DM5EQ7F Pain MG30-MG3Z Investigative [6]
RO3 DMRYNJE Discovery agent N.A. Investigative [8]
TNP-ATP DMVZY0X Discovery agent N.A. Investigative [9]
[3H]A317491 DMTBAXD Discovery agent N.A. Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
4 AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-98.
5 Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
7 Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
8 Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol. 2006 Feb;147 Suppl 2:S132-43.
9 Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
10 Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol. 2003 Dec 15;553(Pt 3):683-94.